Module 5: Safety Pharmacology
Recorded On: 12/23/2025
With such a diverse set of modalities, from small molecules to biologics, including cell and gene therapies, the decision on how to conduct safety pharmacology studies (or not conduct them at all) could be critical to keeping a drug development program on track. This presentation will focus on considerations for conducting standalone safety pharmacology studies, implementing safety pharmacology endpoints within toxicology studies, or not conducting safety pharmacology studies in support of regulatory submission. When conducting safety pharmacology studies, the critical concern is how to follow the regulations for the new chemical or biological entity and provide the most robust data/results to evaluate safety. This presentation will provide an overview to determine the best approach for your program. Topics covered will be the regulations that support safety pharmacology, the vital organ systems that make up the core battery of studies required prior to first-in-human studies, examples of study designs, and a summary of changes to cardiovascular safety pharmacology based on the revised ICH S7B Q&As for both in vitro and in vivo QT assessments.
Brian M. Roche, PhD, DSP, DABT
Executive Director of Global Safety Pharmacology
Charles River Laboratories
Dr. Brian Roche is the General Manager at Charles River Laboratories' Kansas site. He has more than 25 years of experience in preclinical drug development, through multiple roles, with a focus on conducting research from early pharmacology through GLP safety pharmacology studies. In his previous role as the Executive Director of Global Safety Pharmacology at Charles River Laboratories, he provided scientific expertise and leadership on behalf of the Global Safety Pharmacology portfolio.
Dr. Roche received his doctorate in cardiovascular physiology from Ohio State University in 2000 under the mentorship of Dr. Robert Hamlin. He continued his education at Ohio State as a postdoctoral research fellow until 2002. He is an active member of the international scientific community and served as President of the Safety Pharmacology Society in 2021.
Dr. Roche is dual boarded as both a Toxicologist (DABT) and Safety Pharmacologist (DSP), has published 25 peer-reviewed scientific papers and a book chapter.